Neue Antibiotika zur Therapie von Atemwegsinfektionen

 

 Permissions and Reprints

Zusammenfassung

Der Bedarf an neuen Antibiotika ist aufgrund vielfältiger Resistenzentwicklungen groß. Die Resistenz bei Streptococcus pneumoniae gegenüber Makroliden und Penicillinen wird in den USA bereits auf über 30 % beziffert. Die Zulassung neuer Antibiotika, insbesondere solche mit neuem Wirkmechanismus, ist seit vielen Jahren rückläufig, so dass in Zukunft mit einem Mangel an wirksamen Therapieoptionen gerechnet werden muss. Neue Substanzen mit guter In-vitro-Aktivität gegenüber Pneumokokken haben sich nicht in allen Fällen als klinisch unbedenklich erwiesen, wie es zum Beispiel für mehrere Chinolone zutrifft. Ebenso konnte Daptomycin, ein Lipopeptid mit neuartigem Wirkprinzip, aufgrund der Deaktivierung durch Surfactant bei Atemwegserkrankungen nicht überzeugen. Etabliert haben sich bei den Chinolonen Levofloxacin und Moxifloxacin, das seit 2002 auch als i. v.-Zubereitung zur Verfügung steht. Bei den Ketoliden sind Telithromycin (nur oral) und bei den Azaliden Azithromycin (seit 2005 auch als i. v.-Zubereitung) im Handel. Linezolid ist das bisher einzige zugelassene Oxazolidinon. Im Laufe des Jahres 2006 ist in Deutschland mit der Zulassung eines neuen Tetracyclinderivats (Tigecyclin) zu rechnen. Als neues Carbapenemen wurde Ertapenem im Jahr 2003 zugelassen, ein weiteres Antibiotikum aus dieser Gruppe, Doripenem, befindet sich noch in der klinischen Entwicklung.

Abstract

The need for new antibiotics is ongoing in view of manifold resistance developments. The resistance of Streptococcus pneumoniae against macrolides and penicillins in the USA already amounts to more than 30 %. The approval of new antibiotics, particularly those with a new mode of action, has been decreasing over the past years which is anticipated to result in a lack of resourceful therapy options in the future. Some new substances with good in vitro activity against S. pneumoniae have turned out to raise safety issues as shown for a number of quinolones. Likewise daptomycin, a lipopeptide with a new mechanism of action, did not show satisfying results due to its inactivation by surfactant. Established quinolones are levofloxacin and moxifloxacin, the latter being available as i. v. formulation since 2002. For ketolides, telithromycin (oral) and for azalides azithromycin (since 2005 as i. v. formulation) are available for antimicrobial therapy. Linezolid is the only approved oxazolidinone. Tigecycline, a tetracycline derivate, will be approved in 2006 in Germany. The latest approval regarding carbapenems was ertapenem in 2003, while doripenem, a new antibiotic from this group, is still under clinical development.

Literatur

• 1 Bosso J A. The antimicrobial armamentarium: evaluating current and future treatment options.  Pharmacotherapy. 2005;  25 55S-62S
  PubMedGoogle Scholar
• 2 Talbot Jr G H, Bradley J, Edwards J E. et al . Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.  Clin Infect Dis. 2006;  42 (5) 657-668
  CrossrefPubMedGoogle Scholar
• 3 Stahlmann R. Clinical toxicological aspects of fluoroquinolones.  Toxicol Lett. 2002;  127 269-277
  CrossrefPubMedGoogle Scholar
• 4 NN .Full Prescribing Information for Avelox® IV. Bayer Health Care 2005
  Google Scholar
• 5 Finch R, Schurmann D, Collins O. et al . Randomized controlled trial of sequential intravenous (i. v.) and oral moxifloxacin compared with sequential i. v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.  Antimicrob Agents Chemother. 2002;  46 1746-1754
  CrossrefPubMedGoogle Scholar
• 6 Anzueto A, Niederman M S, Pearle J. et al . Community-Acquired Pneumonia Recovery in the Elderly Study Group. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.  Clin Infect Dis. 2006;  42 73-81
  CrossrefPubMedGoogle Scholar
• 7 Balfour J A, Figgitt D P. Telithromycin.  Drugs. 2001;  61 815-829
  PubMedGoogle Scholar
• 8 Jalava J, Kataja J, Seppala H. et al . In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species.  Antimicrob Agents Chemother. 2001;  45 789-793
  CrossrefPubMedGoogle Scholar
• 9 Hammerschlag M R, Roblin P M, Bebear C M. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens.  J Antimicrob Chemother. 2001;  48 25-31
  PubMedGoogle Scholar
• 10 Khair O A, Andrews J M, Honeybourne D. et al . Lung concentrations of telithromycin after oral dosing.  J Antimicrob Chemother. 2001;  47 837-840
  CrossrefPubMedGoogle Scholar
• 11 Hagberg L, Torres A, Rensburg D van. et al . Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia.  Infection. 2002;  30 378-386
  CrossrefPubMedGoogle Scholar
• 12 Reinert R R. Clinical efficacy of ketolides in the treatment of respiratory tract infections.  J Antimicrob Chemother. 2004;  53 918-927
  CrossrefPubMedGoogle Scholar
• 13 Cao Z, Zhong P, Ruan X. et al . Ribosome affinity and the prolonged molecular postantibiotic effect of cethromycin (ABT-773) in Haemophilus influenzae.  Int J Antimicrob Agents. 2004;  24 362-368
  PubMedGoogle Scholar
• 14 Conte Jr J E, Golden J A, Kipps J. et al . Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.  Antimicrob Agents Chemother. 2004;  48 3508-3515
  CrossrefPubMedGoogle Scholar
• 15 Garcia I, Pascual A, Ballesta S. et al . Accumulation and activity of cethromycin (ABT-773) within human polymorphonuclear leucocytes.  J Antimicrob Chemother. 2003;  52 24-28
  CrossrefPubMedGoogle Scholar
• 16 Zhanel G G, Walters M, Noreddin A. et al . The ketolides: a critical review.  Drugs. 2002;  62 1771-1804
  CrossrefPubMedGoogle Scholar
• 17 NN .Full Prescribing Information for Zithromax® IV. Pfizer 2002
  Google Scholar
• 18 Peters D H, Friedel H A, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.  Drugs. 1992;  44 750-799
  CrossrefPubMedGoogle Scholar
• 19 Foulds G, Shepard R M, Johnson R B. The pharmacokinetics of azithromycin in human serum and tissues.  J Antimicrob Chemother. 1990;  25 73-82
  CrossrefPubMedGoogle Scholar
• 20 Luke D R, Foulds G, Cohen S F. et al . Safety, toleration, and pharmacokinetics of intravenous azithromycin.  Antimicrob Agents Chemother. 1996;  40 2577-2581
  PubMedGoogle Scholar
• 21 Chiu L M, Menhinick A M, Johnson P W. et al . Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers.  J Antimicrob Chemother. 2002;  50 1075-1079
  CrossrefPubMedGoogle Scholar
• 22 Rodvold K A, Danziger L H, Gotfried M H. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.  Antimicrob Agents Chemother. 2003;  47 2450-2457
  CrossrefPubMedGoogle Scholar
• 23 Zimmermann T, Laufen H, Riedel K D. et al . Comparative tolerability of intravenous azithromycin, clarithromycin and erythromycin in healthy volunteers: results of a double-blind, double-dummy, four-way crossover study.  Clin Drug Invest. 2001;  21 527-536
  CrossrefPubMedGoogle Scholar
• 24 Diekema D I, Jones R N. Oxazolidinones: a review.  Drugs. 2000;  59 7-16
  PubMedGoogle Scholar
• 25 Clemett D, Markham A. Linezolid.  Drugs. 2000;  59 815-827
  CrossrefPubMedGoogle Scholar
• 26 Gee T, Ellis R, Marshall G. et al . Pharmacokinetics and tissue penetration of linezolid following multiple oral doses.  Antimicrob Agents Chemother. 2001;  45 1843-1846
  CrossrefPubMedGoogle Scholar
• 27 NN. Fachinformation zu Zyvoxid®. Pharmacia GmbH 2001
  Google Scholar
• 28 Rubinstein E, Cammarata S, Oliphant T. et al . Linezolid (PNU-100 766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.  Clin Infect Dis. 2001;  32 402-412
  CrossrefPubMedGoogle Scholar
• 29 Green S L, Maddox J C, Huttenbach E D. Linezolid and reversible myelosuppression.  JAMA. 2001;  285 1291
  CrossrefPubMedGoogle Scholar
• 30 Humphrey S J, Curry J T, Turman C N. et al . Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid.  J Infect Dis. 2001;  37 548-563
  PubMedGoogle Scholar
• 31 Bonfiglio G, Russo G, Nicoletti G. Recent developments in carbapenems.  Expert Opin Investig Drugs. 2002;  11 529-544
  CrossrefPubMedGoogle Scholar
• 32 Livermore D M, Carter M W, Bagel S. et al . In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia.  Antimicrob Agents Chemother. 2001;  45 1860-1867
  CrossrefPubMedGoogle Scholar
• 33 Fuchs P C, Barry A L, Brown S D. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers.  Antimicrob Agents Chemother. 2001;  45 1915-1918
  CrossrefPubMedGoogle Scholar
• 34 Goldstein E J, Citron D M, Vreni Merriam M C. et al . Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.  Antimicrob Agents Chemother. 2000;  44 2389-2394
  CrossrefPubMedGoogle Scholar
• 35 NN. Fachinformation zu Invanz®. MSD Haar 2005
  Google Scholar
• 36 Ortiz-Ruiz G, Caballero-Lopez J, Friedland I R. et al . Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.  Clin Inf Dis. 2002;  34 1076-1083
  CrossrefPubMedGoogle Scholar
• 37 Ge Y, Wikler M A, Sahm D F. et al . In vitro antimicrobial activity of doripenem, a new carbapenem.  Antimicrob Agents Chemother. 2004;  48 1384-1396
  CrossrefPubMedGoogle Scholar
• 38 NN .Full Prescribing Information for Cubicin®. Cubist Pharmaceuticals 2005
  Google Scholar
• 39 Silverman J A, Mortin L I, Vanpraagh A D. et al . Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.  J Infect Dis. 2005;  191 2149-2152
  CrossrefPubMedGoogle Scholar
• 40 NN .Full Prescribing Information for Tygacil®. Wyeth Pharmaceuticals 2005
  Google Scholar
• 41 Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.  J Chemother. 2005;  17 12-22
  PubMedGoogle Scholar
• 42 Saravolatz L D, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.  Clin Infect Dis. 2003;  37 1210-1215
  CrossrefPubMedGoogle Scholar
• 43 Amsden G W, Kuye O, Wei G C. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers.  J Clin Pharmacol. 2002;  42 444-449
  CrossrefPubMedGoogle Scholar

Dr. med. Matthias Kruse

Campus Benjamin Franklin · Inst. für Klinische Pharmakologie und Toxikologie, Abteilung Toxikologie

Garystraße 5

14195 Berlin

Email: matthias.kruse@charite.de